Novel strategies to improve mesothelioma therapy
- Institution
- UNIVERSITY OF HAWAII AT MANOA, HI
- Principal investigator
- Haining Yang
- Funding
- $525K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY Exposure to asbestos fibers is the major risk factor for the development of malignant mesothelioma (MM). We demonstrated that asbestos fibers induce HMGB1 translocation from the nucleus to the cytoplasm, inducing autophagy, a protective mechanism for mesothelial cells survival after asbestos exposure and contributing to malignant transformation. Our findings that autophagy is constitutionally activated in MM cells explains MM chemoresistance. Antidepressant drugs (ADs) were shown to block autophagy and our preliminary data suggested that ADs, well-tolerated drugs, inhibited autophagy in MM cells. Moreover, we discovered that a mitochondrial protein called Mcl-1 blocks chemotherapy-induced apoptosis. Inhibition Mcl-1 increased the effects of chemotherapy five-fold, suggesting that the combination of ADs with Mcl-1 inhibitor may be particularly effective in treating MM. Here we propose to test our hypothesis that autophagy MM growth and chemo-resistance, and that ADs, by inhibiting autophagy, increase the sensitivity of MM to chemo-induced apoptosis, which can be further enhanced by Mcl-1 inhibition. To address this hypothesis, we will examine the following aims: AIM 1: To investigate the mechanisms responsible for the resistance of MM cells to chemotherapy. AIM 2: To investigate whether ADs and the Mcl-1 inhibitor increase the efficacy of chemotherapy in MM in mouse models. AIM 3: To investigate, using biopsies from MM patients, the effects of ADs and the Mcl-1 inhibitor, AZD-5991, on tumor cells and the tumor microenvironment, and assess survival. Our novel and unique reagents and resources will help us understand the specific functions of HMGB1 and the related mechanisms that induce autophagy and facilitate MM progression, which may therefore be the most clinically relevant targets for intervention. Using ADs and the Mcl-1 inhibitor to help sensitize MM to chemotherapy will be extremely translational. This study is of great impact to accelerate the development of more effective therapeutic strategies to improve the prognosis of this devastating malignancy.
Research team
- Michele CarbonePI
- Robert Taylor RipleyPI
- Haining YangPI
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF HAWAII AT MANOA
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · University of Hawaii at Manoa68
Project 3: A Novel Simultaneous Multiparametric MRI Approach for the Quantitative Assessment of Non-alcoholic Fatty Liver Disease
Christoph Alexander Rettenmeier · $267K · 2022–2027
- NIH · University of Hawaii at Manoa64
Assessment of the joint influence of methylmercury and selenium upon postnatal brain development and risk for psychiatric disorders
Matthew William Pitts · $392K · 2024–2027
- NIH · University of Hawaii at Manoa46
Investigating multifactorial beta-catenin activation in hepatocellular cancers
Xin Chen · $490K · 2022–2026